PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Congratulations Dr. Kim on new AAAHC leadership position (AGA)
- When RVUs Go Wrong: Red Flags for Physicians (Medscape)
- GI Side Effects of Immune Checkpoint Inhibitors Linked to Colon Adenoma Risk (GI & Hepatology News)
- Would You Track Your Stools Like You Track Your Steps? (Bloomberg)
- Good news, bad news for gastroenterology (Becker’s GI & Endoscopy)
- Addressing Colonoscopy Burden due to Artificial Intelligence Devices for Polyp Detection (Gastro Journal)
- Gastro Center of Maryland Expands to Bethesda and Silver Spring, Broadening Access to GI Care in the DMV (USA Today)
- To Improve CRC Screening in Patients Aged 45-49, Just Send Them a FIT Kit (GI & Endoscopy News)
